Stay updated on Fostamatinib in wAIHA Clinical Trial

Sign up to get notified when there's something new on the Fostamatinib in wAIHA Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fostamatinib in wAIHA Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy assessment of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA) in a Phase 3 clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:17:01.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that subjects must have a diagnosis of primary or secondary warm Antibody Autoimmune Hemolytic Anemia (wAIHA) and meet certain health conditions. Previously, no information was provided in this section.
    Difference
    16%
    Check dated 2024-05-22T19:55:28.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T23:12:42.000Z thumbnail image

Stay in the know with updates to Fostamatinib in wAIHA Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fostamatinib in wAIHA Clinical Trial page.